Market Overview

Potential 21% Upside Seen For Shares Of Recent IPO Penumbra

Share:

BMO Capital Markets started coverage of Penumbra Inc (NYSE: PEN) with an Outperform rating and price target of $86, implying potential upside of 21 percent.

Although it's a recent IPO, the brokerage pointed out that the company’s 2015 revenue rose 53 percent to $186 million, including $141 million (up 39.2 percent ex-fx) of Neurovascular and $45 million (up 134.9 percent ex-fx) of Peripheral Vascular product sales. Notably, the company generates 30 percent of revenue from outside the U.S.

“Given its differentiated technology, double-digit revenue growth, and path to sustainable profitability, we believe that Penumbra is positioned to deliver results,” analyst Joanne Wuensch wrote in a note.

The company’s key revenue driver is its ischemic stroke products, namely its Penumbra Aspiration system. The company’s latest ACE 68 (launched 2Q16) has improved catheter trackability and decreased procedure times.

Further, the analyst noted that the publication of the MR. CLEAN study changed the treatment paradigm for ischemic stroke, providing the clinical evidence for minimally invasive thrombectomy treatment.

Wuensch added that momentum should continue with new products, clinical data, and continued expansion of the stroke market, and expects the company to deliver double-digit revenue growth.

But, the analyst continued that investors undervaluing the rapidly growing Peripheral Vascular franchise. The franchise includes peripheral embolization and peripheral thrombectomy devices. Key products include the Ruby Coil System, Penumbra Occlusion Device or POD, and Indigo System.

“We will keep an eye on: 1) the publication of the PRISM data, which should benefit its Indigo Thrombectomy System; 2) increasing attention to the peripheral market; and 3) leverage in its Peripheral product portfolio,” Wuensch noted.

At time of writing, shares of Penumbra rose 3.64 percent to $73.45.

Latest Ratings for PEN

DateFirmActionFromTo
Oct 2020Canaccord GenuityAssumesBuy
Sep 2020BTIGInitiates Coverage OnBuy
Sep 2020B of A SecuritiesDowngradesBuyNeutral

View More Analyst Ratings for PEN
View the Latest Analyst Ratings

 

Related Articles (PEN)

View Comments and Join the Discussion!

Posted-In: BMO Capital Markets Joanne WuenschAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com